Global Tumor Radioimmunotherapy Market Growth (Status and Outlook) 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
The global Tumor Radioimmunotherapy market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LPI (LP Information)' newest research report, the “Tumor Radioimmunotherapy Industry Forecast” looks at past sales and reviews total world Tumor Radioimmunotherapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Tumor Radioimmunotherapy sales for 2023 through 2029. With Tumor Radioimmunotherapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Radioimmunotherapy industry.
This Insight Report provides a comprehensive analysis of the global Tumor Radioimmunotherapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Tumor Radioimmunotherapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Radioimmunotherapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Radioimmunotherapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Radioimmunotherapy.
United States market for Tumor Radioimmunotherapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Tumor Radioimmunotherapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Tumor Radioimmunotherapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Tumor Radioimmunotherapy players cover Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Radioimmunotherapy market by product type, application, key players and key regions and countries.
Segmentation by Type:
Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
The global Tumor Radioimmunotherapy market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LPI (LP Information)' newest research report, the “Tumor Radioimmunotherapy Industry Forecast” looks at past sales and reviews total world Tumor Radioimmunotherapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Tumor Radioimmunotherapy sales for 2023 through 2029. With Tumor Radioimmunotherapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tumor Radioimmunotherapy industry.
This Insight Report provides a comprehensive analysis of the global Tumor Radioimmunotherapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Tumor Radioimmunotherapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tumor Radioimmunotherapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Radioimmunotherapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Radioimmunotherapy.
United States market for Tumor Radioimmunotherapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Tumor Radioimmunotherapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Tumor Radioimmunotherapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Tumor Radioimmunotherapy players cover Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Radioimmunotherapy market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Beta-emitting
- Targeted Alpha Therapy
- Solid Tumor
- Non Hodgkin Lymphoma
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Beta-emitting
- Targeted Alpha Therapy
- Solid Tumor
- Non Hodgkin Lymphoma
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Bayer
- Novartis
- Lantheus
- Aurobindo Pharma
- Mundipharma
- China Isotope & Radiation
- Curium Pharmaceuticals
- Gilead Sciences
- Clarity Pharmaceuticals
- Curasight
- Nordic Nanovector
- Philogen
- RadioMedix
- Telix Pharmaceuticals
- Orano Med
- Actinium Pharmaceuticals
- Y-mAbs Therapeutics
- Fusion Pharmaceuticals
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Tumor Radioimmunotherapy Market Size 2019-2030
2.1.2 Tumor Radioimmunotherapy Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Tumor Radioimmunotherapy by Country/Region, 2019, 2023 & 2030
2.2 Tumor Radioimmunotherapy Segment by Type
2.2.1 Beta-emitting
2.2.2 Targeted Alpha Therapy
2.3 Tumor Radioimmunotherapy Market Size by Type
2.3.1 Tumor Radioimmunotherapy Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Tumor Radioimmunotherapy Market Size Market Share by Type (2019-2024)
2.4 Tumor Radioimmunotherapy Segment by Application
2.4.1 Solid Tumor
2.4.2 Non Hodgkin Lymphoma
2.5 Tumor Radioimmunotherapy Market Size by Application
2.5.1 Tumor Radioimmunotherapy Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Tumor Radioimmunotherapy Market Size Market Share by Application (2019-2024)
3 TUMOR RADIOIMMUNOTHERAPY MARKET SIZE BY PLAYER
3.1 Tumor Radioimmunotherapy Market Size Market Share by Player
3.1.1 Global Tumor Radioimmunotherapy Revenue by Player (2019-2024)
3.1.2 Global Tumor Radioimmunotherapy Revenue Market Share by Player (2019-2024)
3.2 Global Tumor Radioimmunotherapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TUMOR RADIOIMMUNOTHERAPY BY REGION
4.1 Tumor Radioimmunotherapy Market Size by Region (2019-2024)
4.2 Global Tumor Radioimmunotherapy Annual Revenue by Country/Region (2019-2024)
4.3 Americas Tumor Radioimmunotherapy Market Size Growth (2019-2024)
4.4 APAC Tumor Radioimmunotherapy Market Size Growth (2019-2024)
4.5 Europe Tumor Radioimmunotherapy Market Size Growth (2019-2024)
4.6 Middle East & Africa Tumor Radioimmunotherapy Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Tumor Radioimmunotherapy Market Size by Country (2019-2024)
5.2 Americas Tumor Radioimmunotherapy Market Size by Type (2019-2024)
5.3 Americas Tumor Radioimmunotherapy Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumor Radioimmunotherapy Market Size by Region (2019-2024)
6.2 APAC Tumor Radioimmunotherapy Market Size by Type (2019-2024)
6.3 APAC Tumor Radioimmunotherapy Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Tumor Radioimmunotherapy Market Size by Country (2019-2024)
7.2 Europe Tumor Radioimmunotherapy Market Size by Type (2019-2024)
7.3 Europe Tumor Radioimmunotherapy Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Tumor Radioimmunotherapy by Region (2019-2024)
8.2 Middle East & Africa Tumor Radioimmunotherapy Market Size by Type (2019-2024)
8.3 Middle East & Africa Tumor Radioimmunotherapy Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TUMOR RADIOIMMUNOTHERAPY MARKET FORECAST
10.1 Global Tumor Radioimmunotherapy Forecast by Region (2025-2030)
10.1.1 Global Tumor Radioimmunotherapy Forecast by Region (2025-2030)
10.1.2 Americas Tumor Radioimmunotherapy Forecast
10.1.3 APAC Tumor Radioimmunotherapy Forecast
10.1.4 Europe Tumor Radioimmunotherapy Forecast
10.1.5 Middle East & Africa Tumor Radioimmunotherapy Forecast
10.2 Americas Tumor Radioimmunotherapy Forecast by Country (2025-2030)
10.2.1 United States Market Tumor Radioimmunotherapy Forecast
10.2.2 Canada Market Tumor Radioimmunotherapy Forecast
10.2.3 Mexico Market Tumor Radioimmunotherapy Forecast
10.2.4 Brazil Market Tumor Radioimmunotherapy Forecast
10.3 APAC Tumor Radioimmunotherapy Forecast by Region (2025-2030)
10.3.1 China Tumor Radioimmunotherapy Market Forecast
10.3.2 Japan Market Tumor Radioimmunotherapy Forecast
10.3.3 Korea Market Tumor Radioimmunotherapy Forecast
10.3.4 Southeast Asia Market Tumor Radioimmunotherapy Forecast
10.3.5 India Market Tumor Radioimmunotherapy Forecast
10.3.6 Australia Market Tumor Radioimmunotherapy Forecast
10.4 Europe Tumor Radioimmunotherapy Forecast by Country (2025-2030)
10.4.1 Germany Market Tumor Radioimmunotherapy Forecast
10.4.2 France Market Tumor Radioimmunotherapy Forecast
10.4.3 UK Market Tumor Radioimmunotherapy Forecast
10.4.4 Italy Market Tumor Radioimmunotherapy Forecast
10.4.5 Russia Market Tumor Radioimmunotherapy Forecast
10.5 Middle East & Africa Tumor Radioimmunotherapy Forecast by Region (2025-2030)
10.5.1 Egypt Market Tumor Radioimmunotherapy Forecast
10.5.2 South Africa Market Tumor Radioimmunotherapy Forecast
10.5.3 Israel Market Tumor Radioimmunotherapy Forecast
10.5.4 Turkey Market Tumor Radioimmunotherapy Forecast
10.6 Global Tumor Radioimmunotherapy Forecast by Type (2025-2030)
10.7 Global Tumor Radioimmunotherapy Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Tumor Radioimmunotherapy Forecast
11 KEY PLAYERS ANALYSIS
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Tumor Radioimmunotherapy Product Offered
11.1.3 Bayer Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Bayer Main Business Overview
11.1.5 Bayer Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Tumor Radioimmunotherapy Product Offered
11.2.3 Novartis Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Lantheus
11.3.1 Lantheus Company Information
11.3.2 Lantheus Tumor Radioimmunotherapy Product Offered
11.3.3 Lantheus Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Lantheus Main Business Overview
11.3.5 Lantheus Latest Developments
11.4 Aurobindo Pharma
11.4.1 Aurobindo Pharma Company Information
11.4.2 Aurobindo Pharma Tumor Radioimmunotherapy Product Offered
11.4.3 Aurobindo Pharma Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Aurobindo Pharma Main Business Overview
11.4.5 Aurobindo Pharma Latest Developments
11.5 Mundipharma
11.5.1 Mundipharma Company Information
11.5.2 Mundipharma Tumor Radioimmunotherapy Product Offered
11.5.3 Mundipharma Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Mundipharma Main Business Overview
11.5.5 Mundipharma Latest Developments
11.6 China Isotope & Radiation
11.6.1 China Isotope & Radiation Company Information
11.6.2 China Isotope & Radiation Tumor Radioimmunotherapy Product Offered
11.6.3 China Isotope & Radiation Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 China Isotope & Radiation Main Business Overview
11.6.5 China Isotope & Radiation Latest Developments
11.7 Curium Pharmaceuticals
11.7.1 Curium Pharmaceuticals Company Information
11.7.2 Curium Pharmaceuticals Tumor Radioimmunotherapy Product Offered
11.7.3 Curium Pharmaceuticals Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Curium Pharmaceuticals Main Business Overview
11.7.5 Curium Pharmaceuticals Latest Developments
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Information
11.8.2 Gilead Sciences Tumor Radioimmunotherapy Product Offered
11.8.3 Gilead Sciences Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Gilead Sciences Main Business Overview
11.8.5 Gilead Sciences Latest Developments
11.9 Clarity Pharmaceuticals
11.9.1 Clarity Pharmaceuticals Company Information
11.9.2 Clarity Pharmaceuticals Tumor Radioimmunotherapy Product Offered
11.9.3 Clarity Pharmaceuticals Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Clarity Pharmaceuticals Main Business Overview
11.9.5 Clarity Pharmaceuticals Latest Developments
11.10 Curasight
11.10.1 Curasight Company Information
11.10.2 Curasight Tumor Radioimmunotherapy Product Offered
11.10.3 Curasight Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Curasight Main Business Overview
11.10.5 Curasight Latest Developments
11.11 Nordic Nanovector
11.11.1 Nordic Nanovector Company Information
11.11.2 Nordic Nanovector Tumor Radioimmunotherapy Product Offered
11.11.3 Nordic Nanovector Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Nordic Nanovector Main Business Overview
11.11.5 Nordic Nanovector Latest Developments
11.12 Philogen
11.12.1 Philogen Company Information
11.12.2 Philogen Tumor Radioimmunotherapy Product Offered
11.12.3 Philogen Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Philogen Main Business Overview
11.12.5 Philogen Latest Developments
11.13 RadioMedix
11.13.1 RadioMedix Company Information
11.13.2 RadioMedix Tumor Radioimmunotherapy Product Offered
11.13.3 RadioMedix Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 RadioMedix Main Business Overview
11.13.5 RadioMedix Latest Developments
11.14 Telix Pharmaceuticals
11.14.1 Telix Pharmaceuticals Company Information
11.14.2 Telix Pharmaceuticals Tumor Radioimmunotherapy Product Offered
11.14.3 Telix Pharmaceuticals Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Telix Pharmaceuticals Main Business Overview
11.14.5 Telix Pharmaceuticals Latest Developments
11.15 Orano Med
11.15.1 Orano Med Company Information
11.15.2 Orano Med Tumor Radioimmunotherapy Product Offered
11.15.3 Orano Med Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Orano Med Main Business Overview
11.15.5 Orano Med Latest Developments
11.16 Actinium Pharmaceuticals
11.16.1 Actinium Pharmaceuticals Company Information
11.16.2 Actinium Pharmaceuticals Tumor Radioimmunotherapy Product Offered
11.16.3 Actinium Pharmaceuticals Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Actinium Pharmaceuticals Main Business Overview
11.16.5 Actinium Pharmaceuticals Latest Developments
11.17 Y-mAbs Therapeutics
11.17.1 Y-mAbs Therapeutics Company Information
11.17.2 Y-mAbs Therapeutics Tumor Radioimmunotherapy Product Offered
11.17.3 Y-mAbs Therapeutics Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Y-mAbs Therapeutics Main Business Overview
11.17.5 Y-mAbs Therapeutics Latest Developments
11.18 Fusion Pharmaceuticals
11.18.1 Fusion Pharmaceuticals Company Information
11.18.2 Fusion Pharmaceuticals Tumor Radioimmunotherapy Product Offered
11.18.3 Fusion Pharmaceuticals Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Fusion Pharmaceuticals Main Business Overview
11.18.5 Fusion Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Tumor Radioimmunotherapy Market Size 2019-2030
2.1.2 Tumor Radioimmunotherapy Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Tumor Radioimmunotherapy by Country/Region, 2019, 2023 & 2030
2.2 Tumor Radioimmunotherapy Segment by Type
2.2.1 Beta-emitting
2.2.2 Targeted Alpha Therapy
2.3 Tumor Radioimmunotherapy Market Size by Type
2.3.1 Tumor Radioimmunotherapy Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Tumor Radioimmunotherapy Market Size Market Share by Type (2019-2024)
2.4 Tumor Radioimmunotherapy Segment by Application
2.4.1 Solid Tumor
2.4.2 Non Hodgkin Lymphoma
2.5 Tumor Radioimmunotherapy Market Size by Application
2.5.1 Tumor Radioimmunotherapy Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Tumor Radioimmunotherapy Market Size Market Share by Application (2019-2024)
3 TUMOR RADIOIMMUNOTHERAPY MARKET SIZE BY PLAYER
3.1 Tumor Radioimmunotherapy Market Size Market Share by Player
3.1.1 Global Tumor Radioimmunotherapy Revenue by Player (2019-2024)
3.1.2 Global Tumor Radioimmunotherapy Revenue Market Share by Player (2019-2024)
3.2 Global Tumor Radioimmunotherapy Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TUMOR RADIOIMMUNOTHERAPY BY REGION
4.1 Tumor Radioimmunotherapy Market Size by Region (2019-2024)
4.2 Global Tumor Radioimmunotherapy Annual Revenue by Country/Region (2019-2024)
4.3 Americas Tumor Radioimmunotherapy Market Size Growth (2019-2024)
4.4 APAC Tumor Radioimmunotherapy Market Size Growth (2019-2024)
4.5 Europe Tumor Radioimmunotherapy Market Size Growth (2019-2024)
4.6 Middle East & Africa Tumor Radioimmunotherapy Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Tumor Radioimmunotherapy Market Size by Country (2019-2024)
5.2 Americas Tumor Radioimmunotherapy Market Size by Type (2019-2024)
5.3 Americas Tumor Radioimmunotherapy Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumor Radioimmunotherapy Market Size by Region (2019-2024)
6.2 APAC Tumor Radioimmunotherapy Market Size by Type (2019-2024)
6.3 APAC Tumor Radioimmunotherapy Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Tumor Radioimmunotherapy Market Size by Country (2019-2024)
7.2 Europe Tumor Radioimmunotherapy Market Size by Type (2019-2024)
7.3 Europe Tumor Radioimmunotherapy Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Tumor Radioimmunotherapy by Region (2019-2024)
8.2 Middle East & Africa Tumor Radioimmunotherapy Market Size by Type (2019-2024)
8.3 Middle East & Africa Tumor Radioimmunotherapy Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL TUMOR RADIOIMMUNOTHERAPY MARKET FORECAST
10.1 Global Tumor Radioimmunotherapy Forecast by Region (2025-2030)
10.1.1 Global Tumor Radioimmunotherapy Forecast by Region (2025-2030)
10.1.2 Americas Tumor Radioimmunotherapy Forecast
10.1.3 APAC Tumor Radioimmunotherapy Forecast
10.1.4 Europe Tumor Radioimmunotherapy Forecast
10.1.5 Middle East & Africa Tumor Radioimmunotherapy Forecast
10.2 Americas Tumor Radioimmunotherapy Forecast by Country (2025-2030)
10.2.1 United States Market Tumor Radioimmunotherapy Forecast
10.2.2 Canada Market Tumor Radioimmunotherapy Forecast
10.2.3 Mexico Market Tumor Radioimmunotherapy Forecast
10.2.4 Brazil Market Tumor Radioimmunotherapy Forecast
10.3 APAC Tumor Radioimmunotherapy Forecast by Region (2025-2030)
10.3.1 China Tumor Radioimmunotherapy Market Forecast
10.3.2 Japan Market Tumor Radioimmunotherapy Forecast
10.3.3 Korea Market Tumor Radioimmunotherapy Forecast
10.3.4 Southeast Asia Market Tumor Radioimmunotherapy Forecast
10.3.5 India Market Tumor Radioimmunotherapy Forecast
10.3.6 Australia Market Tumor Radioimmunotherapy Forecast
10.4 Europe Tumor Radioimmunotherapy Forecast by Country (2025-2030)
10.4.1 Germany Market Tumor Radioimmunotherapy Forecast
10.4.2 France Market Tumor Radioimmunotherapy Forecast
10.4.3 UK Market Tumor Radioimmunotherapy Forecast
10.4.4 Italy Market Tumor Radioimmunotherapy Forecast
10.4.5 Russia Market Tumor Radioimmunotherapy Forecast
10.5 Middle East & Africa Tumor Radioimmunotherapy Forecast by Region (2025-2030)
10.5.1 Egypt Market Tumor Radioimmunotherapy Forecast
10.5.2 South Africa Market Tumor Radioimmunotherapy Forecast
10.5.3 Israel Market Tumor Radioimmunotherapy Forecast
10.5.4 Turkey Market Tumor Radioimmunotherapy Forecast
10.6 Global Tumor Radioimmunotherapy Forecast by Type (2025-2030)
10.7 Global Tumor Radioimmunotherapy Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Tumor Radioimmunotherapy Forecast
11 KEY PLAYERS ANALYSIS
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Tumor Radioimmunotherapy Product Offered
11.1.3 Bayer Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Bayer Main Business Overview
11.1.5 Bayer Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis Tumor Radioimmunotherapy Product Offered
11.2.3 Novartis Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Lantheus
11.3.1 Lantheus Company Information
11.3.2 Lantheus Tumor Radioimmunotherapy Product Offered
11.3.3 Lantheus Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Lantheus Main Business Overview
11.3.5 Lantheus Latest Developments
11.4 Aurobindo Pharma
11.4.1 Aurobindo Pharma Company Information
11.4.2 Aurobindo Pharma Tumor Radioimmunotherapy Product Offered
11.4.3 Aurobindo Pharma Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Aurobindo Pharma Main Business Overview
11.4.5 Aurobindo Pharma Latest Developments
11.5 Mundipharma
11.5.1 Mundipharma Company Information
11.5.2 Mundipharma Tumor Radioimmunotherapy Product Offered
11.5.3 Mundipharma Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Mundipharma Main Business Overview
11.5.5 Mundipharma Latest Developments
11.6 China Isotope & Radiation
11.6.1 China Isotope & Radiation Company Information
11.6.2 China Isotope & Radiation Tumor Radioimmunotherapy Product Offered
11.6.3 China Isotope & Radiation Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 China Isotope & Radiation Main Business Overview
11.6.5 China Isotope & Radiation Latest Developments
11.7 Curium Pharmaceuticals
11.7.1 Curium Pharmaceuticals Company Information
11.7.2 Curium Pharmaceuticals Tumor Radioimmunotherapy Product Offered
11.7.3 Curium Pharmaceuticals Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Curium Pharmaceuticals Main Business Overview
11.7.5 Curium Pharmaceuticals Latest Developments
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Information
11.8.2 Gilead Sciences Tumor Radioimmunotherapy Product Offered
11.8.3 Gilead Sciences Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Gilead Sciences Main Business Overview
11.8.5 Gilead Sciences Latest Developments
11.9 Clarity Pharmaceuticals
11.9.1 Clarity Pharmaceuticals Company Information
11.9.2 Clarity Pharmaceuticals Tumor Radioimmunotherapy Product Offered
11.9.3 Clarity Pharmaceuticals Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Clarity Pharmaceuticals Main Business Overview
11.9.5 Clarity Pharmaceuticals Latest Developments
11.10 Curasight
11.10.1 Curasight Company Information
11.10.2 Curasight Tumor Radioimmunotherapy Product Offered
11.10.3 Curasight Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Curasight Main Business Overview
11.10.5 Curasight Latest Developments
11.11 Nordic Nanovector
11.11.1 Nordic Nanovector Company Information
11.11.2 Nordic Nanovector Tumor Radioimmunotherapy Product Offered
11.11.3 Nordic Nanovector Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Nordic Nanovector Main Business Overview
11.11.5 Nordic Nanovector Latest Developments
11.12 Philogen
11.12.1 Philogen Company Information
11.12.2 Philogen Tumor Radioimmunotherapy Product Offered
11.12.3 Philogen Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Philogen Main Business Overview
11.12.5 Philogen Latest Developments
11.13 RadioMedix
11.13.1 RadioMedix Company Information
11.13.2 RadioMedix Tumor Radioimmunotherapy Product Offered
11.13.3 RadioMedix Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 RadioMedix Main Business Overview
11.13.5 RadioMedix Latest Developments
11.14 Telix Pharmaceuticals
11.14.1 Telix Pharmaceuticals Company Information
11.14.2 Telix Pharmaceuticals Tumor Radioimmunotherapy Product Offered
11.14.3 Telix Pharmaceuticals Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Telix Pharmaceuticals Main Business Overview
11.14.5 Telix Pharmaceuticals Latest Developments
11.15 Orano Med
11.15.1 Orano Med Company Information
11.15.2 Orano Med Tumor Radioimmunotherapy Product Offered
11.15.3 Orano Med Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Orano Med Main Business Overview
11.15.5 Orano Med Latest Developments
11.16 Actinium Pharmaceuticals
11.16.1 Actinium Pharmaceuticals Company Information
11.16.2 Actinium Pharmaceuticals Tumor Radioimmunotherapy Product Offered
11.16.3 Actinium Pharmaceuticals Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Actinium Pharmaceuticals Main Business Overview
11.16.5 Actinium Pharmaceuticals Latest Developments
11.17 Y-mAbs Therapeutics
11.17.1 Y-mAbs Therapeutics Company Information
11.17.2 Y-mAbs Therapeutics Tumor Radioimmunotherapy Product Offered
11.17.3 Y-mAbs Therapeutics Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Y-mAbs Therapeutics Main Business Overview
11.17.5 Y-mAbs Therapeutics Latest Developments
11.18 Fusion Pharmaceuticals
11.18.1 Fusion Pharmaceuticals Company Information
11.18.2 Fusion Pharmaceuticals Tumor Radioimmunotherapy Product Offered
11.18.3 Fusion Pharmaceuticals Tumor Radioimmunotherapy Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Fusion Pharmaceuticals Main Business Overview
11.18.5 Fusion Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Tumor Radioimmunotherapy Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ millions)
Table 2. Tumor Radioimmunotherapy Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Beta-emitting
Table 4. Major Players of Targeted Alpha Therapy
Table 5. Tumor Radioimmunotherapy Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ millions)
Table 6. Global Tumor Radioimmunotherapy Market Size by Type (2019-2024) & ($ millions)
Table 7. Global Tumor Radioimmunotherapy Market Size Market Share by Type (2019-2024)
Table 8. Tumor Radioimmunotherapy Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ millions)
Table 9. Global Tumor Radioimmunotherapy Market Size by Application (2019-2024) & ($ millions)
Table 10. Global Tumor Radioimmunotherapy Market Size Market Share by Application (2019-2024)
Table 11. Global Tumor Radioimmunotherapy Revenue by Player (2019-2024) & ($ millions)
Table 12. Global Tumor Radioimmunotherapy Revenue Market Share by Player (2019-2024)
Table 13. Tumor Radioimmunotherapy Key Players Head office and Products Offered
Table 14. Tumor Radioimmunotherapy Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Tumor Radioimmunotherapy Market Size by Region (2019-2024) & ($ millions)
Table 18. Global Tumor Radioimmunotherapy Market Size Market Share by Region (2019-2024)
Table 19. Global Tumor Radioimmunotherapy Revenue by Country/Region (2019-2024) & ($ millions)
Table 20. Global Tumor Radioimmunotherapy Revenue Market Share by Country/Region (2019-2024)
Table 21. Americas Tumor Radioimmunotherapy Market Size by Country (2019-2024) & ($ millions)
Table 22. Americas Tumor Radioimmunotherapy Market Size Market Share by Country (2019-2024)
Table 23. Americas Tumor Radioimmunotherapy Market Size by Type (2019-2024) & ($ millions)
Table 24. Americas Tumor Radioimmunotherapy Market Size Market Share by Type (2019-2024)
Table 25. Americas Tumor Radioimmunotherapy Market Size by Application (2019-2024) & ($ millions)
Table 26. Americas Tumor Radioimmunotherapy Market Size Market Share by Application (2019-2024)
Table 27. APAC Tumor Radioimmunotherapy Market Size by Region (2019-2024) & ($ millions)
Table 28. APAC Tumor Radioimmunotherapy Market Size Market Share by Region (2019-2024)
Table 29. APAC Tumor Radioimmunotherapy Market Size by Type (2019-2024) & ($ millions)
Table 30. APAC Tumor Radioimmunotherapy Market Size by Application (2019-2024) & ($ millions)
Table 31. Europe Tumor Radioimmunotherapy Market Size by Country (2019-2024) & ($ millions)
Table 32. Europe Tumor Radioimmunotherapy Market Size Market Share by Country (2019-2024)
Table 33. Europe Tumor Radioimmunotherapy Market Size by Type (2019-2024) & ($ millions)
Table 34. Europe Tumor Radioimmunotherapy Market Size by Application (2019-2024) & ($ millions)
Table 35. Middle East & Africa Tumor Radioimmunotherapy Market Size by Region (2019-2024) & ($ millions)
Table 36. Middle East & Africa Tumor Radioimmunotherapy Market Size by Type (2019-2024) & ($ millions)
Table 37. Middle East & Africa Tumor Radioimmunotherapy Market Size by Application (2019-2024) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Tumor Radioimmunotherapy
Table 39. Key Market Challenges & Risks of Tumor Radioimmunotherapy
Table 40. Key Industry Trends of Tumor Radioimmunotherapy
Table 41. Global Tumor Radioimmunotherapy Market Size Forecast by Region (2025-2030) & ($ millions)
Table 42. Global Tumor Radioimmunotherapy Market Size Market Share Forecast by Region (2025-2030)
Table 43. Global Tumor Radioimmunotherapy Market Size Forecast by Type (2025-2030) & ($ millions)
Table 44. Global Tumor Radioimmunotherapy Market Size Forecast by Application (2025-2030) & ($ millions)
Table 45. Bayer Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 46. Bayer Tumor Radioimmunotherapy Product Offered
Table 47. Bayer Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 48. Bayer Main Business
Table 49. Bayer Latest Developments
Table 50. Novartis Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 51. Novartis Tumor Radioimmunotherapy Product Offered
Table 52. Novartis Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 53. Novartis Main Business
Table 54. Novartis Latest Developments
Table 55. Lantheus Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 56. Lantheus Tumor Radioimmunotherapy Product Offered
Table 57. Lantheus Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 58. Lantheus Main Business
Table 59. Lantheus Latest Developments
Table 60. Aurobindo Pharma Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 61. Aurobindo Pharma Tumor Radioimmunotherapy Product Offered
Table 62. Aurobindo Pharma Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 63. Aurobindo Pharma Main Business
Table 64. Aurobindo Pharma Latest Developments
Table 65. Mundipharma Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 66. Mundipharma Tumor Radioimmunotherapy Product Offered
Table 67. Mundipharma Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 68. Mundipharma Main Business
Table 69. Mundipharma Latest Developments
Table 70. China Isotope & Radiation Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 71. China Isotope & Radiation Tumor Radioimmunotherapy Product Offered
Table 72. China Isotope & Radiation Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 73. China Isotope & Radiation Main Business
Table 74. China Isotope & Radiation Latest Developments
Table 75. Curium Pharmaceuticals Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 76. Curium Pharmaceuticals Tumor Radioimmunotherapy Product Offered
Table 77. Curium Pharmaceuticals Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 78. Curium Pharmaceuticals Main Business
Table 79. Curium Pharmaceuticals Latest Developments
Table 80. Gilead Sciences Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 81. Gilead Sciences Tumor Radioimmunotherapy Product Offered
Table 82. Gilead Sciences Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 83. Gilead Sciences Main Business
Table 84. Gilead Sciences Latest Developments
Table 85. Clarity Pharmaceuticals Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 86. Clarity Pharmaceuticals Tumor Radioimmunotherapy Product Offered
Table 87. Clarity Pharmaceuticals Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 88. Clarity Pharmaceuticals Main Business
Table 89. Clarity Pharmaceuticals Latest Developments
Table 90. Curasight Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 91. Curasight Tumor Radioimmunotherapy Product Offered
Table 92. Curasight Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 93. Curasight Main Business
Table 94. Curasight Latest Developments
Table 95. Nordic Nanovector Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 96. Nordic Nanovector Tumor Radioimmunotherapy Product Offered
Table 97. Nordic Nanovector Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 98. Nordic Nanovector Main Business
Table 99. Nordic Nanovector Latest Developments
Table 100. Philogen Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 101. Philogen Tumor Radioimmunotherapy Product Offered
Table 102. Philogen Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 103. Philogen Main Business
Table 104. Philogen Latest Developments
Table 105. RadioMedix Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 106. RadioMedix Tumor Radioimmunotherapy Product Offered
Table 107. RadioMedix Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 108. RadioMedix Main Business
Table 109. RadioMedix Latest Developments
Table 110. Telix Pharmaceuticals Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 111. Telix Pharmaceuticals Tumor Radioimmunotherapy Product Offered
Table 112. Telix Pharmaceuticals Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 113. Telix Pharmaceuticals Main Business
Table 114. Telix Pharmaceuticals Latest Developments
Table 115. Orano Med Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 116. Orano Med Tumor Radioimmunotherapy Product Offered
Table 117. Orano Med Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 118. Orano Med Main Business
Table 119. Orano Med Latest Developments
Table 120. Actinium Pharmaceuticals Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 121. Actinium Pharmaceuticals Tumor Radioimmunotherapy Product Offered
Table 122. Actinium Pharmaceuticals Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 123. Actinium Pharmaceuticals Main Business
Table 124. Actinium Pharmaceuticals Latest Developments
Table 125. Y-mAbs Therapeutics Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 126. Y-mAbs Therapeutics Tumor Radioimmunotherapy Product Offered
Table 127. Y-mAbs Therapeutics Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 128. Y-mAbs Therapeutics Main Business
Table 129. Y-mAbs Therapeutics Latest Developments
Table 130. Fusion Pharmaceuticals Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 131. Fusion Pharmaceuticals Tumor Radioimmunotherapy Product Offered
Table 132. Fusion Pharmaceuticals Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 133. Fusion Pharmaceuticals Main Business
Table 134. Fusion Pharmaceuticals Latest Developments
Table 1. Tumor Radioimmunotherapy Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ millions)
Table 2. Tumor Radioimmunotherapy Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Beta-emitting
Table 4. Major Players of Targeted Alpha Therapy
Table 5. Tumor Radioimmunotherapy Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ millions)
Table 6. Global Tumor Radioimmunotherapy Market Size by Type (2019-2024) & ($ millions)
Table 7. Global Tumor Radioimmunotherapy Market Size Market Share by Type (2019-2024)
Table 8. Tumor Radioimmunotherapy Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ millions)
Table 9. Global Tumor Radioimmunotherapy Market Size by Application (2019-2024) & ($ millions)
Table 10. Global Tumor Radioimmunotherapy Market Size Market Share by Application (2019-2024)
Table 11. Global Tumor Radioimmunotherapy Revenue by Player (2019-2024) & ($ millions)
Table 12. Global Tumor Radioimmunotherapy Revenue Market Share by Player (2019-2024)
Table 13. Tumor Radioimmunotherapy Key Players Head office and Products Offered
Table 14. Tumor Radioimmunotherapy Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Tumor Radioimmunotherapy Market Size by Region (2019-2024) & ($ millions)
Table 18. Global Tumor Radioimmunotherapy Market Size Market Share by Region (2019-2024)
Table 19. Global Tumor Radioimmunotherapy Revenue by Country/Region (2019-2024) & ($ millions)
Table 20. Global Tumor Radioimmunotherapy Revenue Market Share by Country/Region (2019-2024)
Table 21. Americas Tumor Radioimmunotherapy Market Size by Country (2019-2024) & ($ millions)
Table 22. Americas Tumor Radioimmunotherapy Market Size Market Share by Country (2019-2024)
Table 23. Americas Tumor Radioimmunotherapy Market Size by Type (2019-2024) & ($ millions)
Table 24. Americas Tumor Radioimmunotherapy Market Size Market Share by Type (2019-2024)
Table 25. Americas Tumor Radioimmunotherapy Market Size by Application (2019-2024) & ($ millions)
Table 26. Americas Tumor Radioimmunotherapy Market Size Market Share by Application (2019-2024)
Table 27. APAC Tumor Radioimmunotherapy Market Size by Region (2019-2024) & ($ millions)
Table 28. APAC Tumor Radioimmunotherapy Market Size Market Share by Region (2019-2024)
Table 29. APAC Tumor Radioimmunotherapy Market Size by Type (2019-2024) & ($ millions)
Table 30. APAC Tumor Radioimmunotherapy Market Size by Application (2019-2024) & ($ millions)
Table 31. Europe Tumor Radioimmunotherapy Market Size by Country (2019-2024) & ($ millions)
Table 32. Europe Tumor Radioimmunotherapy Market Size Market Share by Country (2019-2024)
Table 33. Europe Tumor Radioimmunotherapy Market Size by Type (2019-2024) & ($ millions)
Table 34. Europe Tumor Radioimmunotherapy Market Size by Application (2019-2024) & ($ millions)
Table 35. Middle East & Africa Tumor Radioimmunotherapy Market Size by Region (2019-2024) & ($ millions)
Table 36. Middle East & Africa Tumor Radioimmunotherapy Market Size by Type (2019-2024) & ($ millions)
Table 37. Middle East & Africa Tumor Radioimmunotherapy Market Size by Application (2019-2024) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Tumor Radioimmunotherapy
Table 39. Key Market Challenges & Risks of Tumor Radioimmunotherapy
Table 40. Key Industry Trends of Tumor Radioimmunotherapy
Table 41. Global Tumor Radioimmunotherapy Market Size Forecast by Region (2025-2030) & ($ millions)
Table 42. Global Tumor Radioimmunotherapy Market Size Market Share Forecast by Region (2025-2030)
Table 43. Global Tumor Radioimmunotherapy Market Size Forecast by Type (2025-2030) & ($ millions)
Table 44. Global Tumor Radioimmunotherapy Market Size Forecast by Application (2025-2030) & ($ millions)
Table 45. Bayer Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 46. Bayer Tumor Radioimmunotherapy Product Offered
Table 47. Bayer Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 48. Bayer Main Business
Table 49. Bayer Latest Developments
Table 50. Novartis Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 51. Novartis Tumor Radioimmunotherapy Product Offered
Table 52. Novartis Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 53. Novartis Main Business
Table 54. Novartis Latest Developments
Table 55. Lantheus Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 56. Lantheus Tumor Radioimmunotherapy Product Offered
Table 57. Lantheus Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 58. Lantheus Main Business
Table 59. Lantheus Latest Developments
Table 60. Aurobindo Pharma Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 61. Aurobindo Pharma Tumor Radioimmunotherapy Product Offered
Table 62. Aurobindo Pharma Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 63. Aurobindo Pharma Main Business
Table 64. Aurobindo Pharma Latest Developments
Table 65. Mundipharma Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 66. Mundipharma Tumor Radioimmunotherapy Product Offered
Table 67. Mundipharma Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 68. Mundipharma Main Business
Table 69. Mundipharma Latest Developments
Table 70. China Isotope & Radiation Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 71. China Isotope & Radiation Tumor Radioimmunotherapy Product Offered
Table 72. China Isotope & Radiation Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 73. China Isotope & Radiation Main Business
Table 74. China Isotope & Radiation Latest Developments
Table 75. Curium Pharmaceuticals Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 76. Curium Pharmaceuticals Tumor Radioimmunotherapy Product Offered
Table 77. Curium Pharmaceuticals Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 78. Curium Pharmaceuticals Main Business
Table 79. Curium Pharmaceuticals Latest Developments
Table 80. Gilead Sciences Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 81. Gilead Sciences Tumor Radioimmunotherapy Product Offered
Table 82. Gilead Sciences Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 83. Gilead Sciences Main Business
Table 84. Gilead Sciences Latest Developments
Table 85. Clarity Pharmaceuticals Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 86. Clarity Pharmaceuticals Tumor Radioimmunotherapy Product Offered
Table 87. Clarity Pharmaceuticals Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 88. Clarity Pharmaceuticals Main Business
Table 89. Clarity Pharmaceuticals Latest Developments
Table 90. Curasight Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 91. Curasight Tumor Radioimmunotherapy Product Offered
Table 92. Curasight Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 93. Curasight Main Business
Table 94. Curasight Latest Developments
Table 95. Nordic Nanovector Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 96. Nordic Nanovector Tumor Radioimmunotherapy Product Offered
Table 97. Nordic Nanovector Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 98. Nordic Nanovector Main Business
Table 99. Nordic Nanovector Latest Developments
Table 100. Philogen Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 101. Philogen Tumor Radioimmunotherapy Product Offered
Table 102. Philogen Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 103. Philogen Main Business
Table 104. Philogen Latest Developments
Table 105. RadioMedix Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 106. RadioMedix Tumor Radioimmunotherapy Product Offered
Table 107. RadioMedix Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 108. RadioMedix Main Business
Table 109. RadioMedix Latest Developments
Table 110. Telix Pharmaceuticals Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 111. Telix Pharmaceuticals Tumor Radioimmunotherapy Product Offered
Table 112. Telix Pharmaceuticals Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 113. Telix Pharmaceuticals Main Business
Table 114. Telix Pharmaceuticals Latest Developments
Table 115. Orano Med Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 116. Orano Med Tumor Radioimmunotherapy Product Offered
Table 117. Orano Med Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 118. Orano Med Main Business
Table 119. Orano Med Latest Developments
Table 120. Actinium Pharmaceuticals Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 121. Actinium Pharmaceuticals Tumor Radioimmunotherapy Product Offered
Table 122. Actinium Pharmaceuticals Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 123. Actinium Pharmaceuticals Main Business
Table 124. Actinium Pharmaceuticals Latest Developments
Table 125. Y-mAbs Therapeutics Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 126. Y-mAbs Therapeutics Tumor Radioimmunotherapy Product Offered
Table 127. Y-mAbs Therapeutics Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 128. Y-mAbs Therapeutics Main Business
Table 129. Y-mAbs Therapeutics Latest Developments
Table 130. Fusion Pharmaceuticals Details, Company Type, Tumor Radioimmunotherapy Area Served and Its Competitors
Table 131. Fusion Pharmaceuticals Tumor Radioimmunotherapy Product Offered
Table 132. Fusion Pharmaceuticals Tumor Radioimmunotherapy Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 133. Fusion Pharmaceuticals Main Business
Table 134. Fusion Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Tumor Radioimmunotherapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Tumor Radioimmunotherapy Market Size Growth Rate 2019-2030 ($ millions)
Figure 6. Tumor Radioimmunotherapy Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Tumor Radioimmunotherapy Sales Market Share by Country/Region (2023)
Figure 8. Tumor Radioimmunotherapy Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Tumor Radioimmunotherapy Market Size Market Share by Type in 2023
Figure 10. Tumor Radioimmunotherapy in Solid Tumor
Figure 11. Global Tumor Radioimmunotherapy Market: Solid Tumor (2019-2024) & ($ millions)
Figure 12. Tumor Radioimmunotherapy in Non Hodgkin Lymphoma
Figure 13. Global Tumor Radioimmunotherapy Market: Non Hodgkin Lymphoma (2019-2024) & ($ millions)
Figure 14. Global Tumor Radioimmunotherapy Market Size Market Share by Application in 2023
Figure 15. Global Tumor Radioimmunotherapy Revenue Market Share by Player in 2023
Figure 16. Global Tumor Radioimmunotherapy Market Size Market Share by Region (2019-2024)
Figure 17. Americas Tumor Radioimmunotherapy Market Size 2019-2024 ($ millions)
Figure 18. APAC Tumor Radioimmunotherapy Market Size 2019-2024 ($ millions)
Figure 19. Europe Tumor Radioimmunotherapy Market Size 2019-2024 ($ millions)
Figure 20. Middle East & Africa Tumor Radioimmunotherapy Market Size 2019-2024 ($ millions)
Figure 21. Americas Tumor Radioimmunotherapy Value Market Share by Country in 2023
Figure 22. United States Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 23. Canada Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 24. Mexico Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 25. Brazil Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 26. APAC Tumor Radioimmunotherapy Market Size Market Share by Region in 2023
Figure 27. APAC Tumor Radioimmunotherapy Market Size Market Share by Type (2019-2024)
Figure 28. APAC Tumor Radioimmunotherapy Market Size Market Share by Application (2019-2024)
Figure 29. China Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 30. Japan Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 31. South Korea Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 32. Southeast Asia Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 33. India Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 34. Australia Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 35. Europe Tumor Radioimmunotherapy Market Size Market Share by Country in 2023
Figure 36. Europe Tumor Radioimmunotherapy Market Size Market Share by Type (2019-2024)
Figure 37. Europe Tumor Radioimmunotherapy Market Size Market Share by Application (2019-2024)
Figure 38. Germany Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 39. France Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 40. UK Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 41. Italy Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 42. Russia Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 43. Middle East & Africa Tumor Radioimmunotherapy Market Size Market Share by Region (2019-2024)
Figure 44. Middle East & Africa Tumor Radioimmunotherapy Market Size Market Share by Type (2019-2024)
Figure 45. Middle East & Africa Tumor Radioimmunotherapy Market Size Market Share by Application (2019-2024)
Figure 46. Egypt Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 47. South Africa Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 48. Israel Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 49. Turkey Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 50. GCC Countries Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 51. Americas Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 52. APAC Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 53. Europe Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 54. Middle East & Africa Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 55. United States Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 56. Canada Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 57. Mexico Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 58. Brazil Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 59. China Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 60. Japan Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 61. Korea Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 62. Southeast Asia Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 63. India Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 64. Australia Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 65. Germany Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 66. France Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 67. UK Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 68. Italy Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 69. Russia Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 70. Egypt Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 71. South Africa Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 72. Israel Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 73. Turkey Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 74. GCC Countries Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 75. Global Tumor Radioimmunotherapy Market Size Market Share Forecast by Type (2025-2030)
Figure 76. Global Tumor Radioimmunotherapy Market Size Market Share Forecast by Application (2025-2030)
Figure 1. Tumor Radioimmunotherapy Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Tumor Radioimmunotherapy Market Size Growth Rate 2019-2030 ($ millions)
Figure 6. Tumor Radioimmunotherapy Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Tumor Radioimmunotherapy Sales Market Share by Country/Region (2023)
Figure 8. Tumor Radioimmunotherapy Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Tumor Radioimmunotherapy Market Size Market Share by Type in 2023
Figure 10. Tumor Radioimmunotherapy in Solid Tumor
Figure 11. Global Tumor Radioimmunotherapy Market: Solid Tumor (2019-2024) & ($ millions)
Figure 12. Tumor Radioimmunotherapy in Non Hodgkin Lymphoma
Figure 13. Global Tumor Radioimmunotherapy Market: Non Hodgkin Lymphoma (2019-2024) & ($ millions)
Figure 14. Global Tumor Radioimmunotherapy Market Size Market Share by Application in 2023
Figure 15. Global Tumor Radioimmunotherapy Revenue Market Share by Player in 2023
Figure 16. Global Tumor Radioimmunotherapy Market Size Market Share by Region (2019-2024)
Figure 17. Americas Tumor Radioimmunotherapy Market Size 2019-2024 ($ millions)
Figure 18. APAC Tumor Radioimmunotherapy Market Size 2019-2024 ($ millions)
Figure 19. Europe Tumor Radioimmunotherapy Market Size 2019-2024 ($ millions)
Figure 20. Middle East & Africa Tumor Radioimmunotherapy Market Size 2019-2024 ($ millions)
Figure 21. Americas Tumor Radioimmunotherapy Value Market Share by Country in 2023
Figure 22. United States Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 23. Canada Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 24. Mexico Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 25. Brazil Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 26. APAC Tumor Radioimmunotherapy Market Size Market Share by Region in 2023
Figure 27. APAC Tumor Radioimmunotherapy Market Size Market Share by Type (2019-2024)
Figure 28. APAC Tumor Radioimmunotherapy Market Size Market Share by Application (2019-2024)
Figure 29. China Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 30. Japan Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 31. South Korea Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 32. Southeast Asia Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 33. India Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 34. Australia Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 35. Europe Tumor Radioimmunotherapy Market Size Market Share by Country in 2023
Figure 36. Europe Tumor Radioimmunotherapy Market Size Market Share by Type (2019-2024)
Figure 37. Europe Tumor Radioimmunotherapy Market Size Market Share by Application (2019-2024)
Figure 38. Germany Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 39. France Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 40. UK Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 41. Italy Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 42. Russia Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 43. Middle East & Africa Tumor Radioimmunotherapy Market Size Market Share by Region (2019-2024)
Figure 44. Middle East & Africa Tumor Radioimmunotherapy Market Size Market Share by Type (2019-2024)
Figure 45. Middle East & Africa Tumor Radioimmunotherapy Market Size Market Share by Application (2019-2024)
Figure 46. Egypt Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 47. South Africa Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 48. Israel Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 49. Turkey Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 50. GCC Countries Tumor Radioimmunotherapy Market Size Growth 2019-2024 ($ millions)
Figure 51. Americas Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 52. APAC Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 53. Europe Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 54. Middle East & Africa Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 55. United States Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 56. Canada Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 57. Mexico Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 58. Brazil Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 59. China Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 60. Japan Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 61. Korea Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 62. Southeast Asia Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 63. India Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 64. Australia Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 65. Germany Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 66. France Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 67. UK Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 68. Italy Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 69. Russia Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 70. Egypt Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 71. South Africa Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 72. Israel Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 73. Turkey Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 74. GCC Countries Tumor Radioimmunotherapy Market Size 2025-2030 ($ millions)
Figure 75. Global Tumor Radioimmunotherapy Market Size Market Share Forecast by Type (2025-2030)
Figure 76. Global Tumor Radioimmunotherapy Market Size Market Share Forecast by Application (2025-2030)
